Evidence map›Paper›PMID 38877481›Full record

ArticleBMC cancer2024

CSPG4P12 polymorphism served as a susceptibility marker for esophageal cancer in Chinese population.

Hongxue Xu, Zhenbang Yang, Wenqian Hu, Xianlei Zhou, Zhi Zhang, Xuemei Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hongxue XuSchool of Public Health, North China University of Science and Technology, Tangshan, China.
Zhenbang YangSchool of Public Health, North China University of Science and Technology, Tangshan, China.
Wenqian HuSchool of Public Health, North China University of Science and Technology, Tangshan, China.
Xianlei ZhouSchool of Public Health, North China University of Science and Technology, Tangshan, China.
Zhi ZhangAffiliated Tangshan Gongren Hospital , North China University of Science and Technology, Tangshan, China.
Xuemei ZhangSchool of Public Health, North China University of Science and Technology, Tangshan, China. zhangxuemei@ncst.edu.cn.

Funding

Tangshan Human Resources and Social Security Bureau A202110007
6 · The paper itself

Abstract

backgroundChondroitin sulfate proteoglycan 4 pseudogene 12 (CSPG4P12) has been implicated in the pathogenesis of various cancers. This study aimed to evaluate the association of the CSPG4P12 polymorphism with esophageal squamous cell carcinoma (ESCA) risk and to explore the biological impact of CSPG4P12 expression on ESCA cell behavior.

methodsA case-control study was conducted involving 480 ESCA patients and 480 healthy controls to assess the association between the rs8040855 polymorphism and ESCA risk. The CSPG4P12 rs8040855 genotype was identified using the TaqMan-MGB probe method. Logistic regression model was used to evaluate the association of CSPG4P12 SNP with the risk of ESCA by calculating the odds ratios (OR) and 95% confidence intervals (95%CI ). The effects of CSPG4P12 overexpression on cell proliferation, migration, and invasion were examined in ESCA cell lines. Co-expressed genes were identified via the CBioportal database, with pathway enrichment analyzed using SangerBox. The binding score of CSPG4P12 to P53 was calculated using RNA protein interaction prediction (RPISeq). Additionally, Western Blot analysis was performed to investigate the impact of CSPG4P12 overexpression on the P53/PI3K/AKT signaling pathway.

resultsThe presence of at least one rs8040855 G allele was associated with a reduced susceptibility to ESCA compared to the CC genotype (OR = 0.51, 95%CI = 0.28-0.93, P = 0.03). Stratification analysis revealed that the CSPG4P12 rs8040855 C allele significantly decreased the risk of ESCA among younger individuals (≤ 57 years) and non-drinkers (OR = 0.31, 95%CI = 0.12-0.77, P = 0.01; OR = 0.42, 95%CI=0.20-0.87, P = 0.02, respectively). CSPG4P12 expression was found to be downregulated in ESCA tissues compared to adjacent normal tissues. Overexpression of CSPG4P12 in ESCA cells inhibited their proliferation, migration, and invasion capabilities. Furthermore, Western Blot analysis indicated that CSPG4P12 overexpression led to a reduction in PI3K and p-AKT protein expression levels. P53 silencing rescues the inhibitory effect of CSPG4P12 on p-AKT.

conclusionThe CSPG4P12 rs8040855 variant is associated with reduced ESCA risk and the overexpression of CSPG4P12 inhibited the migration and invasion of ESCA cells by P53/PI3K/AKT pathway. These findings suggest that CSPG4P12 may serve as a novel biomarker for ESCA susceptibility and a potential target for therapeutic intervention.

Indexed as

Chondroitin Sulfate ProteoglycansEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaGenetic Predisposition to DiseaseMembrane ProteinsAgedBiomarkers, TumorCase-Control StudiesCell Line, TumorCell MovementCell ProliferationChinaChondroitin Sulfate Proteoglycan 4East Asian PeopleFemaleGenotypeBiomarkers, TumorChondroitin Sulfate Proteoglycan 4Chondroitin Sulfate ProteoglycansCSPG4 protein, humanMembrane ProteinsCSPG4P12Esophageal cancerGenetic susceptibilityPseudogeneSingle nucleotide polymorphism

Identifiers

PMID38877481
PMCPMC11177360

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.